VSTM Stock Summary and Trading Ideas (Verastem | NASDAQ:VSTM)

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Verastem trades on the NASDAQ stock market under the symbol VSTM.

As of November 6, 2026, VSTM stock price declined to $8.41 with 6,692,007 million shares trading.

VSTM has a beta of 2.15, meaning it tends to be more sensitive to market movements. VSTM has a correlation of 0.11 to the broad based SPY ETF.

VSTM has a market cap of $1.02 billion. This is considered a Small Cap stock.

Last quarter Verastem reported $24 million in Revenue and -$.72 earnings per share. This fell short of revenue expectation by $-3 million and missed earnings estimates by -$.28.

In the last 3 years, VSTM traded as high as $14.22 and as low as $2.10.

The top ETF exchange traded funds that VSTM belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.

VSTM has underperformed the market in the last year with a price return of +6.1% while the SPY ETF gained +10.8%. However, in the short term, VSTM had mixed performance relative to the market. It has outperformed in the last 3 months, returning +42.3% vs -4.1% return in SPY. But in the last 2 weeks, VSTM shares have been beat by the market, returning -16.2% compared to an SPY return of -3.2%.

VSTM support price is $8.85 and resistance is $9.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VSTM shares will trade within this expected range on the day.